CD274 and non-small cell lung carcinoma: Recent studies have proven that anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) antibodies provide significant survival benefits in patients with advanced NSCLC, when compared with standard chemotherapy [1,2,3,4].